Clinical Trial: 18F-grazy-02 PET/CT of Granzyme B Expression for Monitoring Immunotherapy

U.S., July 25 -- ClinicalTrials.gov registry received information related to the study (NCT07724535) titled '18F-grazy-02 PET/CT of Granzyme B Expression for Monitoring Immunotherapy' on June 30.

Brief Summary: This is an open-label PET/CT study to investigate the safety and clinical monitoring value of 18F-grazy-02 in patients with lymphoma or solid tumors receiving immunotherapy, including immune checkpoint inhibition and CAR-T cell therapy.

Study Start Date: June 24

Study Type: INTERVENTIONAL

Condition: Cancer

Intervention: DRUG: 18F-grazy-02

18F-grazy-02 PET/CT: after intravenous injection of 2.96-3.7 MBq/kg body weight of quality-controlled 18F-grazy-02 , a Total-body PET/CT uEXPLORER scanner will be applied.

Recruitment Statu...